

Bacitracin Methylenedisalicylate and Monensin Growing Turkey Feed
(bacitracin methylenedisalicylate and monensin Type C medicated feed)

INDICATIONS FOR USE

For increased rate of weight gain and improved feed efficiency, and for the prevention of coccidiosis caused by *Eimeria adenoeides*, *E. meleagrimitis* and *E. gallopavonis* in growing turkeys.

ACTIVE DRUG INGREDIENTS

Bacitracin (as feed grade bacitracin methylenedisalicylate)^a..... 4 to 50 g/ton*
Monensin, USP^b.....54 to 90 g/ton*

GUARANTEED ANALYSIS

Crude protein, not less than	_____	%
Lysine, not less than	_____	%
Methionine, not less than	_____	%
Crude fat, not less than	_____	%
Crude fiber, not more than	_____	%
Calcium, not less than	_____	%
Calcium, not more than	_____	%
Phosphorus, not less than	_____	%
Salt ¹ , not less than	_____	%
Salt ¹ , not more than	_____	%
Sodium ² , not less than	_____	%
Sodium ² , not more than	_____	%

¹If added

²Shall be guaranteed only when total sodium exceeds that furnished by the maximum salt guarantee.

INGREDIENTS

Each ingredient must be named in accordance with the names and definitions adopted by the Association of American Feed Control Officials.

FEEDING DIRECTIONS

Feed continuously as the sole ration. The optimum level depends upon the severity of coccidiosis exposure.

CAUTION

Do not allow horses, other equines, mature turkeys or guinea fowl access to feed containing monensin. Ingestion of monensin by horses and guinea fowl has been fatal. Some strains of turkey coccidia may be monensin tolerant or resistant. Monensin may interfere with development of immunity to turkey coccidiosis.

WARNING

Withdrawal Periods: No withdrawal period is required when used according to labeling.

Approved by FDA under NADA # 141-540

MANUFACTURED BY

Blue Bird Feed Company
Robin, Indiana 11111

NET WEIGHT ON BAG OR BULK

Lot Number (if applicable): _____

*The final printed feed label should list only a single drug concentration.

^aPennitracin MD 50G® is the proprietary name of the bacitracin methylenedisalicylate formulation (Type A medicated article) approved by FDA under NADA # 141-137.

^bCoban™ is the proprietary name of the monensin formulation (Type A medicated article) approved by FDA under NADA # 38-878 and 130-736.